Endocarditis antithrombotic therapy

Jump to navigation Jump to search

Endocarditis Microchapters


Patient Information


Historical Perspective




Differentiating Infective Endocarditis from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications & Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

Diagnosis and Follow-up

Medical Therapy


Case Studies

Case #1

Endocarditis antithrombotic therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endocarditis antithrombotic therapy

CDC onEndocarditis antithrombotic therapy

Endocarditis antithrombotic therapy in the news

Blogs on Endocarditis antithrombotic therapy

to Hospitals Treating Endocarditis antithrombotic therapy

Risk calculators and risk factors for Endocarditis antithrombotic therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]


In patients with endocarditis, antithrombotic therapy may be administered when needed. The prothrombin time must be carefully monitored as anticoagulants may cause or worsen hemorrhage in patients with endocarditis. Heparin administration should be avoided if possible.

Antithrombotic Therapy

  • Anticoagulants can cause or worsen hemorrhage in patients with endocarditis but may be carefully administered when needed.[1]
  • The prothrombin time should be carefully maintained at an INR of 2.0–3.0.
  • Anticoagulation should be reversed immediately in the event of CNS complications and interrupted for 1–2 weeks after an acute embolic stroke.
  • Avoid heparin administration during active endocarditis if possible.


  1. Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.

Template:WH Template:WS